By Dr. Fabiano de Abreu Agrela
In current medical practice, there is a dangerous structural error: the belief that human biology is a first-degree equation. When a test indicates a hormone deficiency, the instinctive and standardized response is to replace it. However, the human genome does not operate linearly, but rather through a complex web of epistatic interactions. In the practice of hormone replacement therapy, any alteration in the expression of a central gene triggers a systemic chain reaction, potentially silencing or overactivating multiple secondary pathways.
Epistasis is the biological phenomenon where the action of one gene masks, suppresses, or activates the effect of other genes in the same network. Conventional endocrinology often ignores this engineering. Hormones are not just “fuels” circulating in the blood; they act as powerful cellular transcription factors. When we modulate an exogenous hormone (such as testosterone or estradiol), we are not just changing a number on a piece of paper. We are reconfiguring the entire top of a regulatory cascade.
Let’s take as a practical example what we observe in high-precision genomic mapping. The introduction of hormones interacts directly with fundamental genetic markers. A simple replacement can force the overactivation of the CYP19A1 gene (accelerating aromatization and converting androgens into estrogens), alter the expression of the SHBG protein (which dictates hormone bioavailability), and overload hepatic phase 1 and 2 detoxification pathways (such as CYP1A1 and GSTP1).
The result of this linear and segmented view is silent systemic collapse. When trying to resolve an isolated symptom (such as fatigue or low libido), the physician who ignores the patient’s epistatic network can trigger neuroinflammation, severe oxidative stress, and psychiatric fluctuations, since the hormonal pathway is inextricably linked to the synthesis of neurotransmitters and neurotrophic factors, such as BDNF.
Precision medicine demands cold biological mathematics. Introducing a hormone into a metabolic system without knowing the individual’s epistatic vulnerabilities (such as synthetic lethality interactions or phenotypic suppression) is acting blindly. It’s treating the human body, a highly complex supercomputer, using a typewriter manual.
Real health and high performance are not achieved by pushing isolated markers into generic laboratory references, but rather by understanding and respecting the homeostasis of each individual’s source code.
Dr. Fabiano de Abreu Agrela is a Neuroscientist, Genomics Researcher, and Director of the Heraclitus Research and Analysis Center (CPAH).
